The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma

Biomedicine and Pharmacotherapy

Volumn 68, Issue 4, 2014, Pages 413-417

  Pelizzo, M R ^a   Dobrinja, C ^c   Casal Ide, E ^a   Zane, M ^a   Lora, O ^d   Toniato, A ^a   Mian, C ^a   Barollo, S ^a   Izuzquiza, M ^a   Guerrini, J ^c   De Manzini, N ^c   Merante Boschin, I ^a   Rubello, D ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Medical Physics Santa Maria Della Misericordia Hospital   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

BRAF mutation; Papillary thyroid carcinoma; Thyroid cancer

Indexed keywords

B RAF KINASE; IODINE 131; LEVOTHYROXINE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CERVICAL LYMPH NODE; CHILD; CLINICAL FEATURE; DNA EXTRACTION; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; INTRATHYROID PAPILLARY THYROID CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CARCINOMA; THYROIDITIS; CARCINOMA; GENETICS; GENOMICS; ITALY; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; THYROID TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; FEMALE; GENOMICS; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84901621422     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.008     Document Type: Article

References (30)

1. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167.
2. Pelizzo M.R., Merante Boschin I., Toniato A., Piotto A., Pagetta C., Rubello D. Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 2007, 32:440-444.
3. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009, 19:1167-1214.
4. Nikiforova M.N., Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009, 19:1351-1561.
5. Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., Haugen B.R., Klopper J.P., Zhu Z., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009, 94:2092-2098.
6. Ohori N.P., Nikiforova M.N., Schoedel K.E., LeBeau S.O., Hodak S.P., Seethala R.R., et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of follicular lesion of undetermined significance/atypia of undetermined significance. Cancer Cytopathol 2010, 118:17-23.
7. Li X., Abdel-Mageed A.B., Kandil E. BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med 2012, 5:310-315.
8. Pelizzo M.R., Merante Boschin I., Toniato A., Pagetta C., Mian C., Rubello D. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol 2008, 33:359-379.
9. Pelizzo M.R., Boschin Merante I., Barollo S., Pennelli G., Toniato A., Zambonin L., et al. BRAF analysis by fine-needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med 2011, 49:325-329.
10. Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580.
11. Elisei R., Viola D., Torregrossa L., Giannini R., Romei C., Ugolini C., et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 2012, 97:4390-4398.
12. Liu D., Liu Z., Condouris S., Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007, 92:2264-2271.
13. O'Neill C.J., Bullock M., Chou A., Sidhu S.B., Delbridge L.W., et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 2010, 148:1139-1145. [Discussion 1136-1145].
14. Basolo F., Torregrossa L., Giannini R., Miccoli M., Lupi C., Sensi E., et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 2010, 95:4197-4205.
15. Howell G.M., Nikiforova M.N., Carty S.E., Armstrong M.J., Hodak S.P., Stang M.T., et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 2013, 20:47-52.
16. Rossi E.D., Martini M., Capodimonti S., Lombardi C.P., Pontecorvi A., Vellone V.G., et al. BRAF(V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol 2012, 121:291-297.
17. TNM classification of malignant tumors 2009, Wiley-Blackwell, Chichester, West Sussex, UK; Hoboken, NJ, (309 p.). 7th ed. L.H. Sobin, M.K. Gospodarowicz, C. Wittenkind (Eds.).
18. Barollo S., Pennelli G., Vianello F., Watutantrige Fernando S., Negro I., Merante Boschin I., et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with I-131 and 2-[F-18]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol 2010, 163:659-663.
19. Tang K.T., Lee C.H. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010, 73:113-128.
20. Oler G., Camacho C.P., Hojaij F.C., Michaluart P., Riggins G.J., Cerutti J.M. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 2008, 14:4735-4742.
21. Durante C., Puxeddu E., Ferretti E., Morisi R., Moretti S., Bruno R., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007, 92:2840-2843.
22. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90:6373-6379.
23. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090.
24. Kim S.J., Lee K.E., Myong J.P., Park J.H., Jeon Y.K., et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012, 36:310-317.
25. Kim T.Y., Kim W.B., Song J.Y., Rhee Y.S., Gong G., Cho Y.M., et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005, 63:588-593.
26. Liu R.T., Chen Y.J., Chou F.F., Li C.L., Wu W.L., Tsai P.C., et al. No correlation between BRAF(V600E) mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005, 63:461-466.
27. Niemeier L.A., Kuffner Akatsu H. A combined molecularpathologic score improves risk stratification of papillary microcarcinoma. Cancer Cytopathol 2012, 118:2069-2077.
28. Pelizzo M.R., Merante Boschin I., Toniato A., Piotto A., Rubello D. Papillary thyroid microcarcinoma. Long-term outcome in 587 cases compared with published data. Minerva Chir 2007, 62:315-325.
29. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428.
30. Elisei R., Ugolini C., Viola D. BRAF mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93:3943-3950.